8-K: Tonix Pharmaceuticals Collaborates with Bilthoven Biologicals to Advance Mpox Vaccine Development

Tonix Pharmaceuticals has partnered with Bilthoven Biologicals to develop manufacturing processes for its TNX-801 mpox vaccine candidate, aiming for potential GMP manufacturing.

Summary

• Tonix Pharmaceuticals is collaborating with Bilthoven Biologicals (BBio) to advance the development of its mpox vaccine candidate, TNX-801.
• The collaboration focuses on developing manufacturing processes in preparation for potential Good Manufacturing Practice (GMP) manufacturing of TNX-801.
• TNX-801 is a live, replicating, attenuated virus vaccine based on horsepox, designed to prevent mpox and smallpox.
• Preclinical studies have shown that TNX-801 provided immune protection in non-human primates against a lethal challenge of the Clade 1 monkeypox virus.
• The vaccine is administered in a single dose, which is expected to improve acceptance and eliminate partial vaccination issues associated with two-dose regimens.
• The World Health Organization (WHO) has declared the spread of mpox in multiple African countries a public health emergency of international concern for the second time in two years.
• The current outbreak is caused by the Clade 1 monkeypox virus, which has a mortality rate of up to 10% in some regions.
• Tonix believes TNX-801 can be rapidly scaled up for manufacturing and distributed without the need for an ultra-cold supply chain.
• Tonix has received feedback from the FDA on its pre-Investigational New Drug Application (IND) for TNX-801, providing a path to a Phase 1/2 study.

Sentiment

Score: 7

Explanation: The document is positive due to the collaboration and potential for a new vaccine, but there are still risks and uncertainties associated with drug development.

Positives

• The collaboration with Bilthoven Biologicals is expected to accelerate the development of TNX-801.
• TNX-801 is a single-dose vaccine, which could improve acceptance and eliminate issues with two-dose regimens.
• Preclinical data suggests TNX-801 provides strong immune protection and prevents clinical disease.
• The vaccine has the potential to be manufactured at scale and distributed without an ultra-cold supply chain.
• The FDA feedback provides a clear path for clinical development of TNX-801.
• TNX-801 has the potential to make a global impact on mpox and the risk of smallpox because of its durable T-cell immune response.

Negatives

• The document highlights the severity of the mpox outbreak, including a mortality rate of up to 10% for the Clade 1 strain, indicating the urgency of the situation.
• The document mentions that the current mpox vaccine has had breakthrough cases, highlighting the need for a more effective vaccine.

Risks

• The development of TNX-801 is subject to regulatory approvals and clinical trial success.
• There are risks associated with the manufacturing and scaling up of the vaccine.
• The company faces competition from other vaccine developers.
• The company's financial position may require additional financing to support the development of TNX-801.
• There are risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

Tonix aims to advance TNX-801 through clinical trials and regulatory approvals, with the goal of providing a globally available, affordable, and effective single-dose mpox vaccine. They also plan to expand the viral vector platform for other infectious diseases.

Management Comments

• Jurgen Kwik, CEO of Bilthoven Biologicals, stated that the collaboration underscores the importance of pandemic preparedness.
• Seth Lederman, CEO of Tonix Pharmaceuticals, expressed excitement about collaborating with BBio to accelerate the development of the mpox vaccine candidate.
• Dr. Lederman also emphasized the need for a single-dose mpox vaccine due to the pandemic potential of the disease.

Industry Context

This announcement is relevant given the ongoing mpox outbreaks and the need for more effective and accessible vaccines. The collaboration between Tonix and BBio highlights the importance of global partnerships in addressing public health emergencies. The development of a single-dose vaccine is a significant step forward, as it addresses some of the limitations of current two-dose regimens.

Comparison to Industry Standards

• The current mpox vaccine is a two-dose regimen, while TNX-801 is being developed as a single-dose vaccine, which could improve compliance and effectiveness.
• The document mentions that the current mpox vaccine has had breakthrough cases, suggesting that TNX-801 may offer superior protection.
• The document highlights that TNX-801 has the potential to be manufactured at scale and distributed without an ultra-cold supply chain, which is a significant advantage over some existing vaccines.
• The document references the Serum Institute of India, a major vaccine manufacturer, as part of the Cyrus Poonawalla Group, which is a significant player in the global vaccine market.

Stakeholder Impact

• Shareholders may view the collaboration positively, as it advances a key product candidate.
• Employees of both Tonix and BBio will be involved in the development and manufacturing of the vaccine.
• Customers, including healthcare providers and patients, may benefit from a new, more effective mpox vaccine.
• Suppliers of raw materials and equipment may see increased demand.
• Creditors may view the collaboration as a positive development for the company's financial prospects.

Next Steps

• Tonix and BBio will work together to develop manufacturing processes for TNX-801.
• Tonix plans to advance TNX-801 through clinical trials.
• Tonix aims to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL.

Key Dates

Keywords

mpox vaccine, TNX-801, Bilthoven Biologicals, vaccine development, infectious disease, public health emergency, GMP manufacturing, preclinical studies, single-dose vaccine, horsepox virus